Research Feature - Mapping An Anxiety Spectrum: A Neurobiological Marker of Severity and Prognosis In Mood and Anxiety Disorders
#ADAA2021Virtual Donald F. Klein Awardee Research Presentation
The current diagnostic system emphasizes discrete categories that may not map on to underlying dimensions of psychopathology. For instance, comorbidity in the anxiety disorders is the norm and it is associated with increased disability, lower remission rates and higher relapse. Epidemiological and genetic data suggests that anxiety disordered patients fall along a spectrum, ranging from those with focal fear, low comorbidity and low negative affectivity on one end, to those with diffuse anxiety, high comorbidity and high negative affectivity on the other. fMRI work has indicated heightened threat reactivity along this spectrum, however evidence suggests that an EEG marker of motivated attention to threatening stimuli, the late positive potential (LPP) becomes blunted in individuals with more diffuse anxiety/higher levels of negative affectivity. This webinar will describe results from our recent NIH-funded work that used multiple neurobiological measures to test a novel hypothesis – that comorbidity load in the anxiety disorders is characterized by a unique, multi-level brain profile that can account for comorbidity’s deleterious effects on outcome, beyond what would be expected if comorbidity was simply the sum of its parts.
Learning Objectives:
- Identify brain regions associated with the processing of negative information or events
- Describe complementary electroencephalographic (EEG) and functional magnetic resonance imaging (fMRI) approaches to characterizing anxiety pathophysiology
- Understand recent research findings on negative emotion generation in the anxiety disorders
- Discuss novel ways of characterizing the anxiety disorders along a spectrum
2022 Donald F. Klein Early Career Investigator Award